Kymera Stock 130%: $135 Million Buy Boosts Immunology Bet
A major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
This brief explains the asset selection logic behind equal weighted indices and how different asset classes impact portfolio balance.
23,793 articlesA major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
An in-depth look at Warner Bros. Discovery (WBD) earnings, how its streaming ambitions intersect with legacy TV, and ...
A fresh energy shock amid tariff tensions is tightening corporate margins. Markets moved lower as oil surged and poli...
Kraken made a historic move by securing a Federal Reserve master account, but traditional banks aren’t cheering. This...
Dutch Bros is pursuing aggressive growth inside its existing markets, aiming to dramatically increase store counts an...
Global markets surged after President Trump hinted at de-escalation in Iran, easing oil risks and boosting equities. ...
As AI data centers surge, Micron stands at a crossroads. This guide dives into where will Micron stock be by 2030, th...
The latest 2027 COLA projections show a modest uptick, but many retirees still face a gap between benefits and expens...
Ready to dip a modest $100 into crypto? This guide breaks down two strong bets—Solana and Cardano—and shows how to ev...
When a company CEO sells thousands of shares, investors take notice. This guide breaks down what National Vision's so...
Netflix walked away from a blockbuster deal, yet it still raised prices. This personal-finance guide explains what ha...
ETH failed to clear $2,400, hinting at a pullback toward the $2,000 zone. XRP lingers inside a pennant below $1.40, w...